ArticlePediatric surgery international2025
Alterations in gut microbiota and insights into the colonic function by clodronate: a study using short bowel syndrome rat model.
Article in Pediatric surgery international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Massive Small Bowel Resection Induces IFALD-Like Liver Injury in Mice.Yonago acta medica · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPrevious research suggests that clodronate, a vesicular nucleotide transporter inhibitor, may suppress intestinal failure-associated liver disease (IFALD) in short bowel syndrome (SBS). The present study investigated the effects of clodronate on the gut microbiota and colonic barrier in SBS rat model. PURPOSE: Sprague-Dawley rats underwent 90% small bowel resection and then were randomized into three groups (n = 8 each): SBS/TPN (Control), SBS/TPN with low-dose clodronate (Low, 20 mg/kg/day), and SBS/TPN with high-dose clodronate (High, 60 mg/kg/day). After 7 days, fecal and colon samples were collected to analyze the gut microbiota, histological findings, gene expression of tight junction, and inflammatory markers.
resultsWhile alpha diversity showed no significant differences between the groups, high-dose clodronate-induced heterogeneity in the bacterial community structure. At the phylum level, the Firmicutes/Bacteroidota ratio significantly decreased in the High group. The crypt depth at distal colon was significantly deepest in the High group (p = 0.01). The Claudin-1 expression decreased significantly in the Low group in proximal colon (p = 0.019). The NLRP3 and IL-6 expressions in proximal colon showed significant differences among the groups (NLRP3: p < 0.001, IL-6: p = 0.021).
conclusionClodronate-induced alterations in the gut microbiota may contribute to IFALD suppression, albeit with potentially adverse effects on the colonic barrier.
Indexed as
Identifiers
40825872What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.